subscribeSubscribe
price-trendAsk Us
Epclusa`s fast-tracked Chinese approval might be late for Gilead

Epclusa`s fast-tracked Chinese approval might be late for Gilead
Angus Liu FIERCE PHARMA
31 May 2018
Share Share
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Angus Liu FIERCE PHARMA
06 Jan 2018
Share Share
Bristol-Myers Squibb receives CFDA approval for all-oral regimen for HCV Daklinza in combo with Sunvepra

Bristol-Myers Squibb receives CFDA approval for all-oral regimen for HCV Daklinza in combo with Sunvepra
PHARMABIZ
02 May 2017
Share Share
Recent Success in HCV Treatment Brings Relief to Patients

Recent Success in HCV Treatment Brings Relief to Patients
DRUG DEVELOPMENT
07 Nov 2016
Share Share
Japan`s PMDA reviews hep B risk link to hep C therapies

Japan`s PMDA reviews hep B risk link to hep C therapies
EJ Lane FIERCE ASIA
04 May 2016
Share Share
BMS PhIII hep C combo results a milestone for China plans

BMS PhIII hep C combo results a milestone for China plans
EJ Lane FIERCE PHARMA ASIA
22 Feb 2016
Share Share
BMS gets a leg in the China hep C race with PhI for Daklinza

BMS gets a leg in the China hep C race with PhI for Daklinza
EJ Lane FIERCE PHARMA ASIA
19 Nov 2015
Share Share
AbbVie moves closer to Japan`s crowded hep C field with priority review nod

AbbVie moves closer to Japan`s crowded hep C field with priority review nod
 Carly Helfand FIERCE PHARMA
17 Apr 2015
Share Share
Japan pharma market on track for $80B mark by 2020, but obstacles seen

Japan pharma market on track for $80B mark by 2020, but obstacles seen
EJ Lane FIERCE PHARMA ASIA
01 Apr 2015
Share Share